| This week's sponsor is Sarah Cannon. | | |
Today's Rundown
Merck clamps down on lung cancer lead with another solo Keytruda win Mixed reaction to BMS, Nektar’s high-stakes ‘confusing’ I-O trial Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it? Roche punts taselisib after weak data, severe side effects Merck shows Roche up with big survival numbers in squamous lung cancer Bluebird & Celgene’s CAR-T nears 1 year of PFS in multiple myeloma Loxo sees boosted response rates with LOXO-292 Merck and its new multibillion-dollar partners hone plans for marketing onslaught Zymeworks posts early responses to bispecific antibody in HER2+ cancers Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?
Featured Story | | | Sunday, June 3, 2018
Merck’s Keytruda already boasts a standalone approval for lung cancer patients who haven't been treated before, so long as their tumors bear high levels of the PD-L1 biomarker. But it could soon reach beyond that group, thanks to new data presented Sunday. |
|
|
| This week's sponsor is Medidata. | | | As the complexity of precision oncology trials increase, drug developers are facing the paradox of patient scarcity in the presence of data abundance. Using the right technologies can help to solve this paradox. Read our white paper to learn more. |
Top Stories Sunday, June 3, 2018
Nektar Therapeutics’ much-anticipated data from a study pairing its immuno-oncology prospect NKTR-214 with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo seem to have resulted in a lot of head-scratching. Monday, June 4, 2018
Bristol-Myers Squibb’s strategy in lung cancer relies on showing how its new biomarker can help predict who benefits most from specific immunotherapy combinations, and its latest data supports that notion. Turning tumor mutational burden into a routine diagnostic test could be a tougher get. Monday, June 4, 2018
Roche’s experimental PI3K hopeful taselisib is to be ditched after coming up short at this year’s ASCO cancer conference. Sunday, June 3, 2018
At this year's ASCO meeting, squamous lung cancer has elbowed non-squamous disease off center stage—but once again, it's Merck & Co. stealing the spotlight. Sunday, the drugmaker's PD-1 med Keytruda showed it could cut the risk of disease worsening or death by 44%, easily topping similar data from Roche's Tecentriq. Friday, June 1, 2018
Bluebird Bio and Celgene have built upon their already impressive early-stage clinical responses in advanced multiple myeloma, now confirming that their bb2121 CAR-T therapy extended progression-free survival to just shy of one year in a new set of phase 1 data. Saturday, June 2, 2018
Loxo made a big splash with its larotrectinib data at last year’s ASCO Annual Meeting, and in 2018 it’s hoping to make waves with its earlier-stage RET inhibitor LOXO-292. Monday, June 4, 2018
Merck, arguably the belle of the ASCO ball, spent its on-stage time with major new data for its star med Keytruda. But behind the scenes, it huddled up with new partners AstraZeneca and Eisai. The aim? Get the most out of the $14 billion-plus it shelled out on deals with the two companies. Friday, June 1, 2018
Zymeworks unveiled new phase 1 clinical data from its lead bispecific antibody, ZW25, demonstrating an overall response rate of just 36%, the result of 12 partial responses, as a single-agent treatment in a variety of heavily pretreated, HER2-expressing cancers. Sunday, June 3, 2018
The Novartis breast cancer drug Kisqali so far hasn’t lived up to expectations, and the drugmaker’s hoping some strong new data in metastatic patients will help. Whether the results can boost the drug depends on how doctors decide to use them.
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI
UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Presented by: Patheon, part of Thermo Fisher Scientific
Expanding an existing portfolio with lifecycle management strategies does involve some expense, but it’s not nearly as expensive as developing an entirely new drug. Learn about some new areas of exploration, including novel drug combinations and more. Presented by: Patheon, part of Thermo Fisher Scientific
“Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Presented by: eyeforpharma
While every stakeholder is important, their impact on patient access varies. The power of some is waning, while the clout of other, newer influencers is increasing every day. How do you ensure patients, HCPs and payers are all supported? Presented by: Evidera
The new EU HTA Directive requires consistent comparative clinical efficacy assessment of EMA assessed treatments. Sponsored by: Seton Hall Law
4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign
Life science companies are experiencing a significant transformation in how they bring new products to market.
Biomanufacturing - Online 2018 | Online BIO International Convention June 4-7, 2018 | Boston, MA FierceBiotech Executive Breakfast at BIO 2018 – CAR-T 2.0: Innovation Never Stands Still June 6, 2018 | Boston, MA Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA CBI’s IDN Strategy Summit 2018 August 15-16, 2018 | Philadelphia, PA CBI’s 12th Annual Forum on Transparency & Aggregate Spend August 20-22, 2018 | Washington, DC CBI’s 4th Annual Compliance Congress for Specialty Products September 13-14, 2018 | Boston, MA | 